Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Bladder cancer Clinical Trials

Protocol Number Title
2014IS090
A Phase I/II safety, pharmacokinetic, and pharmacodynamic study of APS001F with flucytosine and maltose for the treatment of advanced and/or metastatic solid tumors.
2014NTLS052
Pilot Study of Clone 6 scFv As a Novel Marker for Isolation and Characterization of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer and Bladder Cancer
2015IS163
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
2015IS170
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
2015IS176
A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab* (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-Line Platinum-Containing Chemotherapy
2015NTIS015
Cysview? Blue Light Cystoscopy Registry
2015NTIS142
Clinical Validation of a Urine-Based Assay with Genomic and Epigenomic Markers for Predicting Recurrence During Surveillance for Non-Muscle Invasive Bladder Cancer
2016IS065
An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
2016IS069
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies
2016IS192
A Phase 1, Open-Label, Multicenter, Dose escalation study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection to patients with advanced malignancies
2017CG114
COG APEC1621 - NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) MASTER VERSION CONTROL PROTOCOL
2017IS028
Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFNβ-NIS), in Patients with Refractory Solid Tumors
2017IS061
MT2017-36 :FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors
EAY131-Z1C
EAY131-Z1C: MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
EAY131-Z1I
EAY131-Z1I: MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
FVCTS-2017-25434
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
PEDS-2016-25172
Collaborative Perinatal Project Minnesota Cohort Follow-up Study (CPP-MN 2.0)

17 trials displayed